THERAMetrics announces the intention of Fin Posillipo S.p.A to subscribe an additional 40 million new registered shares

Stans, Switzerland, February 20, 2014 - THERAMetrics holding AG (the "Company" - SIX: TMX) today announces that in the context of the current capital increase out of the existing authorized share capital, which occurs as a private placement to selected investors, Fin Posillipo S.p.A., one of the Company's main shareholders has confirmed that it will subscribe an additional 40 million new registered shares. Fin Posillipo fully trusts the new Leadership team and strategies deployed to turn the business around and successfully re-position the group as an innovative and leading provider of discovery and development services to the biopharmaceutical industry. Since the capital increase occurs as a private placement, the subscription rights of the existing shareholders are being excluded and allocated to a circle of selected investors. About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact: THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.